Irinotecan dysarthria
Irinotecan-based chemotherapy regimens are used worldwide in the treatment of recurrent or advanced gastrointestinal (GI) cancers, in combination with other cytotoxic drugs or monoclonal antibodies. The most common side effects include acute cholinergic syndrome (ACS) mediated through the inhibition … See more A 49-year-old man diagnosed with locally advanced rectal cancer at the end of 2006 was treated with neoadjuvant radiotherapy combined with capecitabine followed by surgery in February 2007. From April to July 2007 he received … See more A 58-year-old man was diagnosed with locally advanced pancreatic adenocarcinoma in October 2013. The patient had a good … See more A 36-year-old woman underwent right hemicolectomy due to adenocarcinoma in July 2009. The pathological stage at diagnosis was … See more In May 2012, a 60-year-old man underwent right hemicolectomy for adenocarcinoma of the right colon. The pathology report showed poorly differentiated adenocarcinoma of the ileocecal valve (stage pT3 N2 M0) … See more WebJul 8, 2009 · The most frequent side effects of irinotecan include acute cholinergic syndrome (ACS), delayed-onset diarrhoea, and bone-marrow suppression [1]. Much more unusual is the occurrence of irinotecan-induced central nervous system (CNS) toxicity with dysarthria as the predominant symptom.
Irinotecan dysarthria
Did you know?
WebMay 1, 2024 · Early diarrhea (occurring during or shortly after infusion of Irinotecan hydrochloride injection) is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. WebJan 18, 2012 · Irinotecan is a prodrug that requires in vivo activation by carboxylesterases to yield its active and potent metabolite, SN-38, which works in a cell cycle phase-specific (S phase) mechanism to...
WebThe topoisomerase I inhibitor irinotecan is a widely used cytotoxic drug [1]. The most frequent side effects of irinotecan include acute cholinergic syn-drome (ACS), delayed-onset diarrhoea, and bone-marrow suppression [1]. Much more unusual is the occurrence of irinotecan-induced central nervous system (CNS) toxicity with dysarthria as the pre- WebJun 28, 2024 · Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case reports and case …
WebMar 21, 2024 · Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, … WebJan 18, 2012 · Irinotecan is a prodrug that requires in vivo activation by carboxylesterases to yield its active and potent metabolite, SN-38, which works in a cell cycle phase-specific (S …
WebJul 23, 2024 · Irinotecan is a topoisomerase-I inhibitor that is commonly used in combination with other chemotherapy agents for gastrointestinal malignancies. It has …
WebJan 18, 2012 · In conclusion, selective irinotecan-induced dysarthria is an unusual and impressive entity, which can occur within minutes of irinotecan infusion. It is potentially related to a relative cholinergic oversensitivity of neurons in the area of the nucleus of the hypoglossal nerve. Though atropine can decrease cholinergic symptoms, it has not been ... great forceWebJul 26, 2024 · The patient was able to tolerate this reaction and received 20 cycles of irinotecan-based chemotherapy despite experiencing the muscle twitching with every cycle at the same onset, duration, and severity. It is possible that competitive metabolism by concomitant medications metabolized by CYP3A4 or UGT1A1 was responsible for this … flisp financeWebAug 11, 2015 · In all cases, dysarthria occurred during the infusion of irinotecan in the first course of treatment, persisted for several hours, and then resolved rapidly without any sequelae. Physical and neurological examinations at the onset of dysarthria revealed no other abnormalities. Imaging studies revealed no abnormal findings. flisp free stateWebJul 1, 2008 · DISCUSSION. The mechanism by which irinotecan and its active metabolite SN-38 binds and inhibits anticholinesterase has been well described; 4, 5 however, the mechanism by which CNS toxicity occurs after irinotecan infusion is unclear. We are aware of four cases of irinotecaninduced dysarthria reported in the literature, 9 – 12 but to the … flisp houses for saleWebApr 1, 2024 · Irinotecan-induced dysarthria has been reported in the literature, but the underlying mechanism of this neurotoxicity remains unclear. Here, we present a 35-year-old female with metastatic colon cancer who experienced dysarthria during irinotecan infusion. great force insurance newport kyWebIrinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies Article Mar 2024 David Bing Zhen Rachel L McDevitt... flisp housesWebMar 21, 2024 · Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, particularly of gastrointestinal origin.Dysarthria secondary to irinotecan has been described as a rare side effect in a few case reports with limited data to recommend appropriate … flisp income bracket